Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1954 1
1957 1
1958 1
1959 1
1961 2
1963 1
1964 1
1965 1
1966 3
1967 1
1970 1
1971 1
1997 1
1998 2
1999 5
2000 1
2001 3
2002 3
2003 3
2004 6
2005 2
2006 3
2007 3
2008 5
2009 4
2010 4
2011 6
2012 8
2013 11
2014 7
2015 13
2016 13
2017 9
2018 8
2019 10
2020 13
2021 13
2022 11
2023 3
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

171 results

Results by year

Filters applied: . Clear all
Page 1
The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer.
Izumi H, Matsumoto S, Liu J, Tanaka K, Mori S, Hayashi K, Kumagai S, Shibata Y, Hayashida T, Watanabe K, Fukuhara T, Ikeda T, Yoh K, Kato T, Nishino K, Nakamura A, Nakachi I, Kuyama S, Furuya N, Sakakibara-Konishi J, Okamoto I, Taima K, Ebi N, Daga H, Yamasaki A, Kodani M, Udagawa H, Kirita K, Zenke Y, Nosaki K, Sugiyama E, Sakai T, Nakai T, Ishii G, Niho S, Ohtsu A, Kobayashi SS, Goto K. Izumi H, et al. Among authors: niho s. Nature. 2021 Dec;600(7888):319-323. doi: 10.1038/s41586-021-04135-5. Epub 2021 Nov 24. Nature. 2021. PMID: 34819663 Free PMC article.
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Nadanaciva S, Sandin R, Mok TS. Wu YL, et al. Among authors: niho s. Lancet Oncol. 2017 Nov;18(11):1454-1466. doi: 10.1016/S1470-2045(17)30608-3. Epub 2017 Sep 25. Lancet Oncol. 2017. PMID: 28958502 Clinical Trial.
Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study.
Senan S, Okamoto I, Lee GW, Chen Y, Niho S, Mak G, Yao W, Shire N, Jiang H, Cho BC. Senan S, et al. Among authors: niho s. Clin Lung Cancer. 2020 Mar;21(2):e84-e88. doi: 10.1016/j.cllc.2019.12.006. Epub 2019 Dec 28. Clin Lung Cancer. 2020. PMID: 31948903 Free article. Clinical Trial.
Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Chawla A, Rosell R, Corral J, Migliorino MR, Pluzanski A, Noonan K, Tang Y, Pastel M, Wilner KD, Wu YL. Mok TS, et al. Among authors: niho s. Drugs. 2021 Feb;81(2):257-266. doi: 10.1007/s40265-020-01441-6. Drugs. 2021. PMID: 33331989 Free PMC article. Clinical Trial.
Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study).
Seto T, Nosaki K, Shimokawa M, Toyozawa R, Sugawara S, Hayashi H, Murakami H, Kato T, Niho S, Saka H, Oki M, Yoshioka H, Okamoto I, Daga H, Azuma K, Tanaka H, Nishino K, Tohnai R, Yamamoto N, Nakagawa K. Seto T, et al. Among authors: niho s. J Immunother Cancer. 2022 Feb;10(2):e004025. doi: 10.1136/jitc-2021-004025. J Immunother Cancer. 2022. PMID: 35105689 Free PMC article. Clinical Trial.
Reply to J. L. Derks et al.
Kenmotsu H, Niho S, Tsuboi M, Wakabayashi M, Eba J, Asamura H, Ohe Y, Watanabe SI. Kenmotsu H, et al. Among authors: niho s. J Clin Oncol. 2021 May 1;39(13):1509-1510. doi: 10.1200/JCO.21.00107. Epub 2021 Mar 4. J Clin Oncol. 2021. PMID: 33661705 No abstract available.
[Tumor markers in lung cancer].
Niho S, Shinkai T. Niho S, et al. Gan To Kagaku Ryoho. 2001 Dec;28(13):2089-93. Gan To Kagaku Ryoho. 2001. PMID: 11791391 Review. Japanese.
171 results